Novartis, Eli Lilly and Amgen-backed cancer immunotherapy developer Surface Oncology has filed for a $75m offering on Nasdaq.

Biopharmaceuticals developer Aslan Pharmaceuticals, which counts AMT, Accuron and Tianda as backers, has filed to raise up to $86.3m in an initial public offering.

The Dell EMC spinout has filed for a $100m initial public offering that will also enable General Electric, Ford and Microsoft to exit.

The personal finance management app developer has filed for an initial public offering in Hong Kong, with InTime, JD.com and SIG in line for exits.

The local services platform is exploring an IPO in Hong Kong at a $60bn valuation, setting up Tencent, Priceline, Xiaomi, Fosun and Wanda for exits.

Existing investor Salesforce invested another $100m in a private placement, as the file storage platform floated above its range at an $8bn+ valuation.

The cancer immunotherapy developer, backed by Stanford University, has closed the offering after the underwriters bought another $18m of shares.

DocuSign, valued at $3bn as of its last funding round, has confidentially filed for an initial public offering that would offer exits to more than a dozen corporate investors.

The cancer immunotherapy developer, backed by GV, Celgene, Novartis and Taiho Ventures, has closed the offering after the underwriters bought another $18m of shares.

The Aptus Therapeutics-backed neurodegenerative disorder drug developer has filed for an $80.5m initial public offering on Nasdaq after raising roughly $30m in VC funding.